TY - JOUR
T1 - Evaluating ApoL1 Genetic Testing Policy Options for Transplant Centers
T2 - A Delphi Consensus Panel Project with Stakeholders
AU - McIntosh, Tristan
AU - Walsh, Heidi
AU - Baldwin, Kari
AU - Iltis, Ana
AU - Mohan, Sumit
AU - Sawinski, Deirdre
AU - Goodman, Melody
AU - Dubois, James M.
N1 - Publisher Copyright:
© 2024 Lippincott Williams and Wilkins. All rights reserved.
PY - 2024/4
Y1 - 2024/4
N2 - BackgroundApolipoprotein L1 (ApoL1) variants G1 and G2 are associated with a higher risk of kidney disease. ApoL1 risk variants are predominantly seen in individuals with sub-Saharan African ancestry. In most transplant centers, potential organ donors are being selectively genetically tested for ApoL1 risk variants. Transplant programs have highly variable ApoL1 testing practices and need guidance on essential ApoL1 clinical policy questions.MethodsWe conducted a Delphi consensus panel focused on ApoL1 clinical policy questions, including who gets tested, who decides whether testing occurs, how test results are shared, who receives test results, and how test results are used. A total of 27 panelists across seven stakeholder groups participated: living kidney donors (n=4), deceased donor family members (n=3), recipients of a deceased donor kidney (n=4), recipients of a living donor kidney (n=4), nephrologists (n=4), transplant surgeons (n=4), and genetic counselors (n=4). Nineteen panelists (70%) identified as Black. The Delphi panel process involved two rounds of educational webinars and three rounds of surveys administered to panelists, who were asked to indicate whether they support, could live with, or oppose each policy option.ResultsThe panel reached consensus on one or more acceptable policy options for each clinical policy question; panelists supported 18 policy options and opposed 15. Key elements of consensus include the following: ask potential donors about African ancestry rather than race; make testing decisions only after discussion with donors; encourage disclosure of test results to blood relatives and organ recipients but do not require it; use test results to inform decision making, but never for unilateral decisions by transplant programs.ConclusionsThe panel generally supported policy options involving discussion and shared decision making among patients, donors, and family stakeholders. There was general opposition to unilateral decision making and prohibiting donation altogether.
AB - BackgroundApolipoprotein L1 (ApoL1) variants G1 and G2 are associated with a higher risk of kidney disease. ApoL1 risk variants are predominantly seen in individuals with sub-Saharan African ancestry. In most transplant centers, potential organ donors are being selectively genetically tested for ApoL1 risk variants. Transplant programs have highly variable ApoL1 testing practices and need guidance on essential ApoL1 clinical policy questions.MethodsWe conducted a Delphi consensus panel focused on ApoL1 clinical policy questions, including who gets tested, who decides whether testing occurs, how test results are shared, who receives test results, and how test results are used. A total of 27 panelists across seven stakeholder groups participated: living kidney donors (n=4), deceased donor family members (n=3), recipients of a deceased donor kidney (n=4), recipients of a living donor kidney (n=4), nephrologists (n=4), transplant surgeons (n=4), and genetic counselors (n=4). Nineteen panelists (70%) identified as Black. The Delphi panel process involved two rounds of educational webinars and three rounds of surveys administered to panelists, who were asked to indicate whether they support, could live with, or oppose each policy option.ResultsThe panel reached consensus on one or more acceptable policy options for each clinical policy question; panelists supported 18 policy options and opposed 15. Key elements of consensus include the following: ask potential donors about African ancestry rather than race; make testing decisions only after discussion with donors; encourage disclosure of test results to blood relatives and organ recipients but do not require it; use test results to inform decision making, but never for unilateral decisions by transplant programs.ConclusionsThe panel generally supported policy options involving discussion and shared decision making among patients, donors, and family stakeholders. There was general opposition to unilateral decision making and prohibiting donation altogether.
KW - apolipoprotein L1 (ApoL1)
KW - CKD
KW - community engagement and health
KW - kidney transplantation
KW - transplant outcomes
KW - transplantation
UR - http://www.scopus.com/inward/record.url?scp=85190483299&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85190483299&partnerID=8YFLogxK
U2 - 10.2215/CJN.0000000000000397
DO - 10.2215/CJN.0000000000000397
M3 - Article
C2 - 38190141
AN - SCOPUS:85190483299
SN - 1555-9041
VL - 19
SP - 494
EP - 502
JO - Clinical Journal of the American Society of Nephrology
JF - Clinical Journal of the American Society of Nephrology
IS - 4
ER -